Yahoo Web Search

Search results

    • Small Business - Cordele Dispatch | Cordele Dispatch

      Cordele Dispatch· 20 hours ago

      Innovent Announces Taletrectinib(ROS1 Inhibitor)Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting PR Newswire SAN FRANCISCO and SUZHOU, China, June 2, 2024 SAN FRANCISCO and

    • Small Business - Picayune Item | Picayune Item

      The Picayune Item· 23 hours ago

      Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC PR Newswire SUZHOU, China, and ROCKVILLE, Md., June 1, 2024 SUZHOU, China ...

    • Small Business - Cordele Dispatch | Cordele Dispatch

      Cordele Dispatch· 1 day ago

      Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib(ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting PR Newswire SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 SAN FRANCISCO, U.S. and

    • Small Business - Salisbury Post | Salisbury Post

      The Salisbury Post· 3 days ago

      Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’ decentralized manufacturing platform in patients with head